Candidate: Vaccine to prevent COVID-19

Category: VAX

Type: Not specified

Status: IIBR’s vaccine prototype has begun to be tested on rodents at its biochemical defense lab, Reuters reported March 31, after Israeli Prime Minister Benjamin Netanyahu issued a statement saying he was informed of “significant progress” in designing the prototype by IIBR’s director Shmuel Shapira, MD.

At a March 24 virtual conference hosted by Jerusalem Venture Partners, IIBR chief innovation officer Eran Zahavy, PhD, said the institute had shifted its entire focus to COVID-19, with three groups trying to develop a vaccine against the novel coronavirus, and other groups researching potential treatments.

Netanyahu directed IIBR, an Israeli government defense research institute, to develop a COVID-19 candidate in February. Netanyahu and the chief of Israel’s military, Lieutenant-General Aviv Kohavi, went into self-isolation at the end of March following exposure to coronavirus carriers. Both men have tested negative for the virus.


COVID-19: 200 Candidates and Counting

To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:

FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.

DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data

KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.

TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.

GEN has also tagged the most common treatment types:

● ANTIVIRAL
● VAX
● ANTIBODY
● RNA

Previous articleValo Therapeutics
Next articleBiovista